European approval of tucatinib (Tukysa) for treatment of HER2-positive locally advanced or metastatic breast cancer

Approval of this oral antineoplastic protein kinase inhibitor of HER2 kinase, in combination with trastuzumab & capecitabine, was based on a trial which found improved progression free survival (HR 0.54, 95%CI 0.42-0.71) and overall survival (0.66; 0.50-0.87) vs control.

Source:

Biospace Inc.